Oxytone Bioscience BV Report issue

For profit Phase 1
Founded: Zeist Netherlands (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2016
NCT02908126
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

oxytocin (syntocinon) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 1)

Postpartum Hemorrhage (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1